LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma

CLINICALTRIALS.GOV IDENTIFIER: NCT03946527

DRUG/TREATMENT: Lanreotide

PHASE: 2

STATUS: Recruiting

SPONSOR: Antonio Fojo, Columbia University

COLLABORATOR: Ipsen

Dr. Jaydira Del Rivero Discusses LAMPARA

DESCRIPTION:

The objectives of this study are:

To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma.
To assess the toxicity and safety of lanreotide in participants with advanced or metastatic paraganglioma/ pheochromocytoma.
To document the effects of lanreotide on markers of biochemical activity in participants with advanced or metastatic paraganglioma/ pheochromocytoma.

Primary endpoints:

Assess efficacy by estimating the tumor growth rate while a patient is enrolled on study and comparing the growth rates on lanreotide to the pre-enrolment growth rate.

Secondary endpoints include measurement of:

Overall survival (OS)
Progression-free survival (PFS)
Overall response rate (ORR) according to RECIST defined as partial response (PR) + complete response (CR)
Magnitude of reduction in levels of 24-hour urinary metanephrines, catecholamines and magnitude of reduction in serum chromogranin A, evaluated every two months while enrolled on study.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT/Principal Investigator:

Antonio Fojo, MD, PhD, Columbia University

PHONE: 212-305-9422

Research Nurse Navigator

EMAIL: cancerclinicaltrials@cumc.columbia.edu

PHONE: 212-342-5162